Research programme: muscular dystrophy and metabolic disorders therapy - UMN Pharma
Latest Information Update: 20 Jun 2011
At a glance
- Originator UMN Pharma
- Developer Crucell; DSM Biologics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Muscular dystrophies; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 20 Jun 2011 Discontinued - Preclinical for Muscular dystrophies in Japan (unspecified route)
- 20 Jun 2011 Discontinued - Preclinical for Obesity in Japan (unspecified route)
- 20 Jun 2011 Discontinued - Preclinical for Type-2 diabetes mellitus in Japan (unspecified route)